From the next year, a large number of effective but expensive imported biologics will confront with “expire of patent,” which makes generic drugs no longer illegal. Up to 2018, most of biologics in the present global market will not be under patent protection, including popular Herceptin, Enbrel, Insulin lispro, Rituximab, Aranesp (darbepoetin alfa), Remicade, etc., which provides a good opportunity for China. Wang Junzhi, Vice Director of National Institutes for Food and Drug Control noted that it would be of great significance to solve the problem of expensive drugs if we can take the opportunity to make generic drugs. In addition, the security and effectiveness of generic drugs have been proved through time since major adverse drug reaction never happened before.

(Source: China IP Magazine)